LIPITOR

This brand name is authorized in Australia, Brazil, Canada, Cyprus, Germany, Ecuador, Finland, Hong Kong, Ireland, Israel, Japan, Malta, Mexico, Nigeria, Netherlands, New Zealand, Singapore, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug LIPITOR contains one active pharmaceutical ingredient (API):

1 Atorvastatin UNII 48A5M73Z4Q - ATORVASTATIN CALCIUM TRIHYDRATE

Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL. Read about Atorvastatin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LIPITOR Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR
LIPITOR Film-coated tablet	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C10AA05	Atorvastatin	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AA HMG CoA reductase inhibitors
Discover more medicines within C10AA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 8213G, 8214H, 8215J, 8521L, 9230T, 9231W, 9232X, 9233Y
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 552820020061917, 552820020062017, 552820020062117, 552820020062217, 552820020062317, 552820020062417, 552820020062517, 552820020062617, 552820020062717
Country: CA	Health Products and Food Branch	Identifier(s): 02230711, 02230713, 02230714, 02243097
Country: DE	Bundesinstitut für Arzneimittel und Medizinprodukte	Identifier(s): 07639372
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 2357-MEE-0716, 2484-MEE-1216, H5000513, H5240513
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 061527, 061538, 061550, 061561, 061584, 061595, 061607, 550124
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 13376, 13390, 13397, 139228, 139231, 139234, 143111, 161997, 18799, 197194, 197197, 198752
Country: HK	Department of Health Drug Office	Identifier(s): 42328, 42329, 42330, 49653
Country: IE	Health Products Regulatory Authority	Identifier(s): 31710, 31731, 31752, 31798, 31819, 31892, 32001, 32038, 32359, 32363, 32399, 32551, 41884, 41885
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 4076, 4077, 4562, 4563
Country: JP	医薬品医療機器総合機構	Identifier(s): 2189015F1023, 2189015F2020
Country: MT	Medicines Authority	Identifier(s): MA1396/00901, MA1396/00902, MA1396/00903, MA1396/00904, MA1396/00905, PI770/12701A
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 413M97
Country: NG	Registered Drug Product Database	Identifier(s): 04-3158, 04-3159, 04-3160, A4-5732
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 98604, 98612, 98620, 98779, 98787
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 14310, 14311, 14312, 14313
Country: SG	Health Sciences Authority	Identifier(s): 09550P, 09551P, 09552P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699532090201, 8699532091420, 8699532091475, 8699532094964, 8699532095015, 8699532095190, 8699532095541, 8699532095619
Country: US	FDA, National Drug Code	Identifier(s): 0071-0155, 0071-0156, 0071-0157, 0071-0158, 55289-800, 55289-861, 55289-870, 63629-1446, 63629-6633, 63629-6768, 63629-6776
Country: ZA	Health Products Regulatory Authority	Identifier(s): 31/7.5/0357, 31/7.5/0358, 31/7.5/0359, 37/7.5/0210